aXichem AB (publ) (“aXichem”), that develops and markets analogue industrial compounds, has received a patent regarding the company's natural analogue capsaicin, phenylcapsaicin, and variants of the product, as a substance for the treatment of leaky gut. The patent significantly contributes to aXichem’s patent portfolio and is commercially valuable, since it protects the company's unique product in an area where phenylcapcaicin, in tests, has shown clear effectiveness.

Leaky gut means that the intestinal wall's protective barrier has weakened and thus lets toxins and bacteria through into the bloodstream. Leaky gut carries the risk of a number of different medical conditions and has therefore received more and more attention in recent years, including in research into the connection between diet and gut health.

aXichem's patent application is entitled "Capsaicyns in the treatment of leaky gut".

“I see great opportunities for phenylcapsaicin in products related to pharmaceutical applications. Thanks to the product showing a good effect in low doses, it is an interesting alternative. The patent is an important step for aXichem and it further strengthens our solid foundation for progress in the company's core businesses as well as in future pharmaceutical areas”, says Torsten Helsing, CEO of aXichem.

aXichem has global patent protection for the molecule phenylcapsaicin, derivatives of phenylcapsaicin, the method of producing the main molecule and derivatives of the molecules. The patent application "Capsaicyns in the treatment of leaky gut" was submitted in November 2020.

The information was submitted, through the care of the contact person, for publication on September 1, 2022, at 8:45 AM CEST.